Patents by Inventor Duncan Casson

Duncan Casson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY
    Publication number: 20170260264
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Application
    Filed: September 20, 2016
    Publication date: September 14, 2017
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
    Patent number: 9447181
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 20, 2016
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • Antagonistic anti-human CD40 monoclonal antibody
    Patent number: 8669352
    Abstract: The present invention provides novel antagonistic anti-human CD40 monoclonal antibodies, methods for generating them and uses thereof.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: March 11, 2014
    Assignee: Fast Forward Pharmaceuticals B.V.
    Inventors: Marcel Theodorus den Hartog, Ruprecht Jules Joost van Neerven, Kevin Stuart Johnson, Robert Duncan Casson
  • Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
    Patent number: 8435523
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 7, 2013
    Assignee: Abbott Research B.V.
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY
    Publication number: 20100278839
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 4, 2010
    Applicant: PANGENETICS 110 BV
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall